Aldeyra Therapeutics, Inc. $ALDX Shares Acquired by 683 Capital Management LLC

683 Capital Management LLC grew its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) by 86.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,530,000 shares of the biotechnology company’s stock after buying an additional 710,000 shares during the quarter. 683 Capital Management LLC owned about 2.54% of Aldeyra Therapeutics worth $7,925,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Global Retirement Partners LLC acquired a new position in Aldeyra Therapeutics during the fourth quarter worth $52,000. Inspirion Wealth Advisors LLC acquired a new position in Aldeyra Therapeutics during the fourth quarter worth $52,000. CIBC Private Wealth Group LLC acquired a new position in Aldeyra Therapeutics during the third quarter worth $55,000. BNP Paribas Financial Markets raised its holdings in Aldeyra Therapeutics by 36.9% during the third quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 2,859 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Aldeyra Therapeutics during the fourth quarter worth $62,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on ALDX. Wall Street Zen raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. BTIG Research reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, March 17th. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price objective (down from $10.00) on shares of Aldeyra Therapeutics in a report on Wednesday, March 18th. Finally, Weiss Ratings downgraded Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aldeyra Therapeutics has an average rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Stock Performance

Aldeyra Therapeutics stock opened at $1.83 on Thursday. The stock has a fifty day moving average of $1.69 and a two-hundred day moving average of $3.48. The company has a market capitalization of $110.39 million, a price-to-earnings ratio of -3.98 and a beta of 1.19. Aldeyra Therapeutics, Inc. has a fifty-two week low of $1.07 and a fifty-two week high of $6.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.07. On average, analysts forecast that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current fiscal year.

Insider Activity at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, CEO Todd C. Brady acquired 250,000 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average price of $1.67 per share, with a total value of $417,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,721,298 shares in the company, valued at approximately $2,874,567.66. This trade represents a 16.99% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 11.80% of the stock is currently owned by corporate insiders.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.